These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 23774148)

  • 21. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
    Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
    Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Crizotinib: an anaplastic lymphoma kinase inhibitor.
    Gadgeel SM; Bepler G
    Future Oncol; 2011 Aug; 7(8):947-53. PubMed ID: 21823889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multicenter ALK testing in non-small-cell lung cancer: results of a round robin test.
    von Laffert M; Penzel R; Schirmacher P; Warth A; Lenze D; Hummel M; Dietel M
    J Thorac Oncol; 2014 Oct; 9(10):1464-9. PubMed ID: 25170635
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Crizotinib administered via nasogastric and percutaneous endoscopic gastrostomy tubes for the successful treatment of ALK-rearranged lung cancer in a patient with poor performance status.
    Tamai K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Katakami N; Tomii K
    Respir Investig; 2013 Mar; 51(1):46-8. PubMed ID: 23561259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders.
    Roskoski R
    Expert Opin Drug Discov; 2013 Sep; 8(9):1165-79. PubMed ID: 23805942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of crizotinib in ALK mutant non-small cell lung cancers that are positive by IHC but negative by FISH compared to FISH positive cases.
    Zanwar S; Noronha V; Joshi A; Patil VM; Kaushal R; Chougule A; Janu A; Mahajan A; Kapoor A; Prabhash K
    Indian J Cancer; 2017; 54(4):678-680. PubMed ID: 30082557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancer.
    Hong X; Chen Q; Ding L; Liang Y; Zhou N; Fang W; Chen X; Wu H
    Oncotarget; 2017 Jun; 8(25):41631-41640. PubMed ID: 28427213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Crizotinib in the treatment of non-small-cell lung cancer.
    Forde PM; Rudin CM
    Expert Opin Pharmacother; 2012 Jun; 13(8):1195-201. PubMed ID: 22594847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer.
    Nilsson RJ; Karachaliou N; Berenguer J; Gimenez-Capitan A; Schellen P; Teixido C; Tannous J; Kuiper JL; Drees E; Grabowska M; van Keulen M; Heideman DA; Thunnissen E; Dingemans AM; Viteri S; Tannous BA; Drozdowskyj A; Rosell R; Smit EF; Wurdinger T
    Oncotarget; 2016 Jan; 7(1):1066-75. PubMed ID: 26544515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of crizotinib among Chinese EML4-ALK-positive, advanced-stage non-small cell lung cancer patients.
    Cao Y; Xiao G; Qiu X; Ye S; Lin T
    PLoS One; 2014; 9(12):e114008. PubMed ID: 25501361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical Efficacy of Crizotinib in Advanced ALK Positive 
Non-small Cell Lung Cancer].
    Zhao J; Zhang K; Zhang L; Wang H
    Zhongguo Fei Ai Za Zhi; 2015 Oct; 18(10):616-20. PubMed ID: 26483333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.
    Huang D; Kim DW; Kotsakis A; Deng S; Lira P; Ho SN; Lee NV; Vizcarra P; Cao JQ; Christensen JG; Kim TM; Sun JM; Ahn JS; Ahn MJ; Park K; Mao M
    Genomics; 2013 Sep; 102(3):157-62. PubMed ID: 23434628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients.
    Gambacorti Passerini C; Farina F; Stasia A; Redaelli S; Ceccon M; Mologni L; Messa C; Guerra L; Giudici G; Sala E; Mussolin L; Deeren D; King MH; Steurer M; Ordemann R; Cohen AM; Grube M; Bernard L; Chiriano G; Antolini L; Piazza R
    J Natl Cancer Inst; 2014 Feb; 106(2):djt378. PubMed ID: 24491302
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting anaplastic lymphoma kinase in lung cancer.
    Shaw AT; Solomon B
    Clin Cancer Res; 2011 Apr; 17(8):2081-6. PubMed ID: 21288922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer.
    Djalalov S; Beca J; Hoch JS; Krahn M; Tsao MS; Cutz JC; Leighl NB
    J Clin Oncol; 2014 Apr; 32(10):1012-9. PubMed ID: 24567430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful desensitization of two patients with ALK-positive lung cancer and hypersensitivity to crizotinib.
    Awad MM; Lax TP; Slawski BR; Shaw AT
    J Thorac Oncol; 2014 Nov; 9(11):1726-8. PubMed ID: 25436807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.
    Kogita A; Togashi Y; Hayashi H; Banno E; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Takeyama Y; Okuno K; Nakagawa K; Nishio K
    Int J Oncol; 2015 Mar; 46(3):1025-30. PubMed ID: 25502629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis.
    Chiari R; Metro G; Iacono D; Bellezza G; Rebonato A; Dubini A; Sperduti I; Bennati C; Paglialunga L; Burgio MA; Baglivo S; Giusti R; Minotti V; Delmonte A; Crinò L
    Lung Cancer; 2015 Nov; 90(2):255-60. PubMed ID: 26395848
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of crizotinib in NSCLC patients.
    Hamilton G; Rath B; Burghuber O
    Expert Opin Drug Metab Toxicol; 2015 May; 11(5):835-42. PubMed ID: 25732197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors.
    Amin AD; Rajan SS; Liang WS; Pongtornpipat P; Groysman MJ; Tapia EO; Peters TL; Cuyugan L; Adkins J; Rimsza LM; Lussier YA; Puvvada SD; Schatz JH
    Cancer Res; 2015 Jul; 75(14):2916-27. PubMed ID: 26018086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.